GlassScriptPhysician profile
Dhamyanthi Sivamohan
NPI 1326146580
$23,059.59
in general payments reported to CMS, 2019-2025
56 companies · $3,323 in 2025
The $3,323 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,941 · 2020: $2,804 · 2021: $3,750 · 2022: $3,275 · 2023: $3,591 · 2024: $3,375 · 2025: $3,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,143.21 |
| Education | $145.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,284.57 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $2,808.76 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,765.54 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $1,666.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,607.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,605.25 | 2020-2025 | Vraylar, Linzess, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $966.44 | 2022-2025 | |
| Amgen INC. | $960.91 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $832.53 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $716.26 | 2021-2025 | Rexulti, Abilify Maintena |
| Horizon Therapeutics Plc | $539.19 | 2019-2022 | |
| Axsome Therapeutics, INC. | $525.33 | 2022-2025 | Auvelity, Sunosi |
| Astellas Pharma US INC | $525.20 | 2020-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $449.02 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $276.02 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhamyanthi Sivamohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.